Peter R. Carroll, MD, MPH, presented “Biochemical Recurrence After Local Therapy: Assessment and Management” for the Grand Rounds in Urology audience in July, 2019.
How to cite: Carroll, Peter R. “Biochemical Recurrence After Local Therapy: Assessment and Management” July, 2019. Accessed Jul 2024. https://grandroundsinurology.com/biochemical-recurrence-after-local-therapy-assessment-and-management/
Biochemical Recurrence After Local Therapy: Assessment and Management – Summary:
Peter R. Carroll, MD, MPH, Taube Family Distinguished Professor in Urology at the University of California, San Francisco, outlines detection and treatment options for biochemical recurrence following a prostatectomy or radiation therapy. He details how recurrence can be detected with PSMA PET imaging, as the majority of cases have PSMA-avid lesions present. Dr. Carroll further notes typical and atypical regional and local areas of recurrence. He also describes a new disease management algorithm for deciding between further radiation therapy or monitoring & localized treatment.
ABOUT THE AUTHOR
Dr. Peter Carroll holds the Ken and Donna Derr-Chevron Professorship in Prostate Cancer and the Taube Family Distinguished Professorship in Urology at the University of California, San Francisco (UCSF). He is also the Associate Director of Strategic Planning and Clinical Services and Program Leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center at UCSF.
Dr. Carroll graduated with honors from Georgetown University School of Medicine. He then went on to complete general surgery training and a urology residency at UCSF, as well as a Fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York City. He has taught at the UCSF Department of Urology since 1986, and he became the department chair in 1996. Under his leadership, the department has been consistently ranked one of the top urology departments in the country by U.S. News and World Report. The department has grown, serving an increasingly larger patient population, expanding its research programs, and attracting future leaders in the field for training. Under Dr. Carroll’s leadership, the department managed an average of over $10 million in research grants that put UCSF in first place for urology funding for five consecutive years. Dr. Carroll also established the UCSF Department of Urology’s Tissue Core, a biobank of blood, urine, and residual prostate, bladder, and renal tissues for more than 6,000 consenting patients. In addition to his many accomplishments at UCSF, Dr. Carroll has authored or co-authored over 650 publications, is an active member of numerous professional medical societies, and is currently principal or co-investigator on numerous scientific studies. He is also Past-President of the American Board of Urology (2006-2008). His drive to perfect nerve-sparing prostatectomy has led to many technical innovations, and his pioneering efforts in standardizing an active surveillance regimen has led to many patients postponing radical treatment while maintaining a low risk of cancer progression.
